2746-14-7

Usage

Uses

1. Used in Pharmaceutical Synthesis:
1-Methylcyclopropanemethanol is used as a synthetic intermediate for the preparation of various pharmaceutical compounds. For instance, it has been utilized in the synthesis of (±)-2-(benzyloxycarbonylamino)-2-(1′-methylcyclopropyl)ethanamide, which may have potential applications in the development of new drugs.
2. Used in Chemical Research:
The compound is also used in chemical research to study the kinetics of gas-phase thermal decomposition. This information is valuable for understanding the compound's behavior under different conditions and can be applied to improve the efficiency of chemical reactions involving 1-Methylcyclopropanemethanol.

InChI:InChI=1/C5H10O/c1-5(4-6)2-3-5/h6H,2-4H2,1H3

Upstream product

• 60111-68-4 1,1,1-tris(bromomethyl)ethane 
• 6206-25-3 methyl 1-methylcyclopropanecarboxylate 
• 75-11-6 diiodomethane 
• 513-42-8 3-hydroxy-2-methyl-1-propene 
• 17314-41-9 2-methyl-4-trimethylstannyl-1-butene 
• 121108-80-3 4-bromo-2-methyl-1,2-epoxybutane 
• 157-46-0 2-Oxa-spiro<3,2>hexan 
• 6914-76-7 1-Methyl-cyclopropanoic acid 
• 71441-76-4 1-methylcyclopropanecarboxylic acid ethyl ester 

Downstream Products

• 13033-53-9 (1-methylcyclopropyl)methyl tosylate 
• 1239269-60-3 4'-({2-methyl-4-[(1-methylcyclopropyl)methyl]-5-oxo-7-propyl-4,5-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-6-yl}methyl)biphenyl-2-carbonitrile 
• 1236764-13-8 1-[(1-methylcyclopropyl)methoxy]-4-nitrobenzene 
• 1221503-69-0 4-bromo-5-(4-fluorophenyl)-3-methyl-1-[(1-methylcyclopropyl)methyl]-1H-pyrazole 
• 1200575-71-8 (1-methylcyclopropyl)methyl 4-{6-[4-(methoxycarbonyl)phenyl]-4H-1,3-benzodioxin-2-yl}piperidine-1-carboxylate 
• 56068-37-2 (E)-4,4-Dimethyl-1-(1-methyl-cyclopropyl)-pent-1-en-3-one 
• 173485-30-8 (+/-)-N-benzyloxycarbonyl-2-(1'-methylcyclopropyl)glycine 
• 139132-43-7 (+/-)-2-(1'-methylcyclopropyl)glycine 
• 951789-81-4 C₁₅H₂₁NO₃ 
• 113235-25-9 (1-Methyl-cyclobutylsulfanyl)-benzene 

Relevant academic research and scientific papers

COMPOUNDS AND METHOD OF USE

This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.

N1-PHENYLPROPANE-1,2-DIAMINE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula A-1, or a salt thereof: Formula A-1, where J, K, Q and R1 are as defined herein, which compounds have properties for inhibiting sodium ion channels found in peripheral and sympathetic neurons. Also described are pharmace

Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2

In our efforts to develop novel small-molecule inhibitors for the treatment of influenza, we utilized molecular modeling and the X-ray crystal structure of the PB2 subunit of the influenza polymerase to optimize a series of acyclic β-amino acid inhibitors, highlighted by compound 4. Compound 4 showed good oral exposure in both rat and mouse. More importantly, it showed strong potency versus multiple influenza-A strains, including pandemic 2009 H1N1 and avian H5N1 strains and showed a strong efficacy profile in a mouse influenza model even when treatment was initiated 48 h after infection. Compound 4 offers good oral bioavailability with great potential for the treatment of both pandemic and seasonal influenza.

Substituted pyrazolylpyrazole derivative and use thereof as herbicide

The invention provides a compound which can effectively control major weeds having higher leaf ages which become a practical problem. Disclosed is a specific pyrazolylpyrazole derivative which is represented by formula (I) and can solve the above-mentioned problem.

Fused ring compound and use thereof

The present invention provides a compound represented by the formula: wherein the symbols are as described in the specification, or a salt thereof, which is useful for preventing/treating eicosanoid-associated diseases such as atherosclerosis, diabetes, obesity, atherothrombosis, asthma, fever, pain, cancer, rheumatism, osteoarthritis and atopic dermatitis, and which has an excellent pharmacological action, physicochemical properties, etc.

Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Reduction of Cyclopropanecarboxylic Acids by Borane, a Chemoselective Reaction Sensitive to Steric Interactions and Reaction Conditions

A number of cyclopropanecarboxylic acids have been reduced by borane in tetrahydrofuran to the corresponding cyclopropyl alcohols. The yield was sensitive to the steric influence of the substituents attached to the ring, the reaction temperature, and the

Compounds for inhibiting β-amyloid peptide release and/or its synthesis

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis.

Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.